Bayer Looks To Turn Aleve Sales Around Following Negative Media Hit
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of OTC naproxen benefited from COX-2 safety concerns initially, but felt repercussions from the National Institutes of Health’s December decision to halt the ADAPT study due to issues surrounding the drug.